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The mitogen activated protein kinase (MAPK)-extracellular regulated kinase 1/2
(ERK1/2) pathway is a central downstream signaling pathway that is activated in cardiac
muscle cells during mechanical and agonist-mediated hypertrophy. Studies in genetic
mouse models deficient in ERK-associated MAPK components pathway have further
reinforced a direct role for this pathway in stress-induced cardiac hypertrophy and
disease. However, more recent studies have highlighted that these signaling pathways
may exert their regulatory functions in a more compartmentalized manner in cardiac
muscle. Emerging data has uncovered specific MAPK scaffolding proteins that tether
MAPK/ERK signaling specifically at the sarcomere and plasma membrane in cardiac
muscle and show that deficiencies in these scaffolding proteins alter ERK activity and
phosphorylation, which are then critical in altering the cardiac myocyte response to
stress-induced hypertrophy and disease progression. In this review, we provide insights
on ERK-associated scaffolding proteins regulating cardiac myofilament function and
their impact on cardiac hypertrophy and disease.
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SCAFFOLD PROTEINS THAT REGULATE ERK-ASSOCIATED
MITOGEN ACTIVATED PROTEIN KINASE FUNCTION:
GROWING IMPORTANCE IN CARDIAC HYPERTROPHY
The mitogen activated protein kinase (MAPK)/extracellular regulated kinase (ERK) signaling
pathway is one of the first blueprints describing how extracellular cues/factors (growth factors and
hormones) generate intracellular signals and converge on the nucleus to drive gene expression
and a wide range of cellular functions (Pearson et al., 2001). How this single pathway regulates
diverse functions and achieves specificity in function in different cell types has been a longstanding
question in the field. Studies have suggested that scaffolding proteins are emerging as playing an
essential role in regulating the MAPK signaling response (Brown and Sacks, 2009). MAPK scaffold
proteins are dynamic entities that (i) directly interact with multiple components of the MAPK
signaling complex, (ii) consolidate or sequester protein interactions to physically insulate the
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MAPK pathway to specific cellular locations as well as (iii)
regulate signal strength and stimulus-specific responses to
efficiently transmit MAPK signals in a spatiotemporal manner
and narrow its actions (Brown and Sacks, 2009). Notable MAPK
scaffolds that regulate ERK signaling include, kinase suppressor
of Ras (KSR) (Kornfeld et al., 1995; Sundaram and Han, 1995;
Therrien et al., 1995), MAPK organizer 1, MORG1 (Vomastek
et al., 2004), MEK partner 1, MP1 (Schaeffer et al., 1998),
paxillin (Ishibe et al., 2003), β-arrestin (Raabo et al., 1992),
and MEKK1 (Karandikar et al., 2000). KSR is one of the best-
characterized mammalian MAPK scaffold proteins (Kornfeld
et al., 1995). KSR is critical in recruiting the Raf/MEK/ERK
complex to the plasma membrane as well as regulating MAPK
signaling strength and duration at this location (Brown and
Sacks, 2009). Its importance was most notable in Caenorhabditis
elegans development as well as immune and cancer cells since
in vivo models deficient in KSR-1 exhibited deficiencies in
ERK activation in a stimulus-specific manner, resulting in
resistance to inflammatory diseases and Ras-mediated cancers
(Nguyen et al., 2002; Lozano et al., 2003; Fusello et al.,
2006).
Recently, MAPK scaffold proteins have been identified in the
heart and shown to play a pivotal role in pathophysiological
cardiac hypertrophy (Figure 1). Cardiac hypertrophy is the
main way in which cardiomyocytes initially adapt to increased
mechanical workload and neurohormonal stimuli to increase
cardiac output and compensate for adverse effects on cardiac
pump function (Bernardo et al., 2010). Physiological cardiac
hypertrophy (i.e., the ‘athlete’s heart’) is characterized by normal
cardiac organization and normal or enhanced cardiac function.
However, pathological cardiac hypertrophy is a key risk factor
for heart failure and is associated with increased interstitial
fibrosis, apoptosis, and cardiac dysfunction (McMullen and
Jennings, 2007). More recently studies have linked Ras-Raf1-
MEK1/2-ERK1/2 signaling pathway in pathological cardiac
hypertrophy (Lorenz et al., 2009b). Both constitutive activation
of Ras (H-Ras-V12) and overexpression of MEK1 in the mouse
heart displayed characteristic features of exaggerated cardiac
hypertrophy (Bueno et al., 2000; Zheng et al., 2004). Inhibition
of the ERK pathway via dominant negative Raf or cardiac specific
deletion of c-raf-1 attenuated pathological cardiac hypertrophy
(Yamaguchi et al., 2004; Goldsmith and Dhanasekaran, 2007).
The recent identification of a new autophosphorylation site of
ERK2 at Thr188 (Thr208 in ERK1) demonstrated a specific
role for ERK signaling in the induction of pathological cardiac
hypertrophy in response to various hypertrophic stimuli (Lorenz
et al., 2009a). Interference with ERKThr188 phosphorylation
attenuated ERK-mediated pathological hypertrophy, but not
physiological cardiac hypertrophy (Ruppert et al., 2013). More
recent efforts have been devoted to understanding how MAPK
scaffold proteins regulate ERK signaling strength and duration
as well as their role in cardiac muscle in the context
of hypertrophy. This review will highlight the subcellular
functions and actions of ERK-associated MAPK scaffolds in
cardiac muscle and pathological cardiac hypertrophy, with a
particular focus on evidence gained from genetic mouse models
(Table 1).
MYOFILAMENT-ASSOCIATED
SCAFFOLDING PROTEINS THAT
REGULATE ERK FUNCTION IN CARDIAC
HYPERTROPHY AND DISEASE
Four and a Half LIM Domain Protein-1
(FHL1)
Studies from our laboratory have reported FHL1 as a novel ERK
associated MAPK scaffold protein that mediates MAPK/ERK
signaling responses at the sarcomere during stress-induced
cardiac hypertrophy (Sheikh et al., 2008; Raskin et al.,
2012). FHL1 is first detected at embryonic day (E) 8.5 in
the mouse heart during early development (Chu et al., 2000).
Although FHL1 is ubiquitously expressed, it is found to be
highly abundant in mammalian striated muscle (Chu et al.,
2000). Various studies have shown that FHL1 interacts with
multiple binding partners, including structural proteins, signal
transducers, transcription regulators, receptors, and channels,
to regulate different biological processes (Shathasivam et al.,
2010). However, most notably in the heart, FHL1 becomes
highly upregulated during hypertrophic conditions in mice
and humans (Hwang et al., 1997, 2000; Chu et al., 2000;
Lim et al., 2001). Studies in FHL1 knockout (Fhl1−/−) mice
demonstrated that FHL1 is dispensable for survival and
basal heart function (Sheikh et al., 2008). However, under
conditions of pressure overload, adult Fhl1−/− hearts displayed
a blunted response to cardiac hypertrophy (Sheikh et al., 2008).
Most notably, Fhl1−/− mice subjected to transverse aortic
constriction (TAC) maintained cardiac function comparable to
sham-operated control mice, and unlike control mice, which
exhibited pathological cardiac hypertrophy and dysfunction
(Sheikh et al., 2008), highlighting that loss of FHL1 is
essential for preservation of cardiac function in pressure
overload.
In vivo studies performed in transgenic mice overexpressing
a constitutively active form of Gαq selectively in the heart,
highlighted that FHL1 intersected with Gαq signaling pathways
(Sheikh et al., 2008). The Gαq signaling pathway has also
been shown to be critical for pressure-overload induced
cardiac hypertrophy (D’Angelo et al., 1997; Wettschureck
et al., 2001). Interestingly, deletion of Fhl1 was shown to be
sufficient to prevent the cardiomyopathy in Gαq overexpressing
transgenic mice (Sheikh et al., 2008). Yeast two-hybrid and
co-immunoprecipitation based assays further identified that
FHL1 could directly interact with MAPK components, Raf1,
MEK2, and ERK2 in vitro and in in vivo (Sheikh et al., 2008).
Immunofluorescence microscopy studies further showed that
the FHL1/Raf-1/ MEK2/ERK2 complex all localized to the
sarcomeric I band, and thus highlighted a MAPK scaffolding
function for FHL1 at the titin N2B region of the sarcomere
(Sheikh et al., 2008).
In terms of downstream effects on MAPK/ERK signaling,
FHL1 overexpression was sufficient to increase ERK1/2
phosphorylation in cardiomyocytes in vitro (Sheikh et al., 2008).
In vivo studies performed in FHL1 deficient settings such as TAC
subjected Fhl1−/− adult hearts as well as double Fhl1−/−/Gαq
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FIGURE 1 | Schemata of the signaling actions of MAPK scaffolding proteins in cardiac hypertrophy and disease. ANKRD1, Ankyrin Repeat Domain 1;
ERK, extracellular signal-regulated kinase; FAK, focal adhesion kinase; FHL1, Four and a half LIM domain protein-1; GATA4, GATA binding protein-4; GPCR, G
Protein Coupled Receptor; IQGAP1, IQ motif-containing guanine-5′-triphosphate hydrolase activating protein; MEK, mitogen-activated protein kinase kinase; SUR-8,
Suppressor of Ras-8.
constitutively overexpressing adult hearts demonstrated a
blunted response to ERK1/2 phosphorylation, suggesting
that FHL1 can positively regulate Raf-1/MEK/ERK-mediated
signaling in a Gαq stimulus-specific manner (Sheikh et al.,
2008). Convergence of these pathways to titin N2B function was
shown in isolated adult Fhl1−/− cardiac muscles subjected to
a maximum extension of 15–20% stretch (Sheikh et al., 2008;
Raskin et al., 2012). Stretched Fhl1−/− cardiac muscles displayed
a loss of upregulation of Elk-1 mRNA (transcriptional target
of ERK1/2 signaling) and diastolic stress when compared with
controls, further demonstrating an impact of loss of FHL1 and
MAPK-ERK signaling on cardiac muscle compliance (Sheikh
et al., 2008; Raskin et al., 2012).
Phosphorylation of titin N2B has been reported to be pivotal
in mediating muscle compliance in cardiomyocytes (Fukuda
et al., 2005). Interestingly, titin N2B isoform expression was
increased in adult Fhl1−/− cardiac muscles and these muscles
were also found to be insensitive to titin N2B phosphorylation-
mediated diastolic reduction, as they intrinsically exhibited
functions associated with maximal titin N2B phosphorylation
(Raskin et al., 2012). In vitro studies demonstrated that ERK2
can directly phosphorylate titin N2B (Ser-3873, Ser-3915,
Ser-3965) and that FHL1 functioned to interfere with ERK2-
mediated titin N2B phosphorylation (Raskin et al., 2012).
Thus, in FHL1 deficient settings titin N2B phosphorylation was
thought to be hyper or maximally phosphorylated correlating
with increased compliance. These studies lead to a model
whereby FHL1 acts to scaffold MAPK components at titin
N2B in order to regulate cardiac muscle compliance (via
titin N2B phosphorylation) and hypertrophic signaling under
conditions of stretch/hypertrophic stress/Gq (Raskin et al.,
2012). Interestingly in FHL1 deficient settings, a unique
role for the MAPK component, ERK2, was identified as
it was no longer tethered to titin N2B but instead “open”
to directly phosphorylate titin N2B to increase compliance
of cardiac muscle as opposed to being sequestered to
participate in hypertrophic signaling (Raskin et al., 2012).
These results suggest that FHL1 functions as a MAPK scaffold
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by directly interacting with Raf-1/MEK2/ ERK2 to physically
insulate the MAPK pathway to the titin N2B region of the
sarcomere in a Gq stimulus-specific manner and efficiently
transmit MAPK signals to regulate cardiac hypertrophy
(Figure 1).
Ankyrin Repeat Domain 1 (ANKRD1)
Recent studies also suggested that ANKRD1 [also known as
cardiac adriamycin responsive protein (CARP)] is an ERK
associated protein that mediates ERK signaling responses
at the sarcomere (titin N2A) during phenylephrine-induced
hypertrophy (Zhong et al., 2015). ANKRD1 is a transcriptional
cofactor and highly expressed in embryonic cardiomyocytes
(Mikhailov and Torrado, 2008). ANKRD1 was shown to
negatively regulate gene expression of cardiac-specific genes
in fetal cardiomyocytes in vitro (Jeyaseelan et al., 1997; Zou
et al., 1997; Kuo et al., 1999). In adult cardiac muscle ANKRD1
expression is developmentally downregulated but was reported
to increase in animal models of cardiac hypertrophy and
human patients with various forms of cardiomyopathy leading
to heart failure (Arber et al., 1997; Kuo et al., 1999; Aihara
et al., 2000; Maeda et al., 2002; Zolk et al., 2003). Genetic
mutations in ANKRD1 were also found to be causative for
hypertrophic and dilated cardiomyopathy (Arimura et al.,
2009; Duboscq-Bidot et al., 2009; Moulik et al., 2009). Based
on the direct interaction between ANKRD1 and titin N2A
region, it was thought that ANKRD1 may play a critical role
in linking stretch-induced signaling pathways and muscle
gene expression (Miller et al., 2003). However, in vivo
studies performed in Ankrd1 knockout mice (Ankrd1−/−)
highlighted an indispensable role for ANKRD1 in the
heart at basal conditions (Bang et al., 2014). In addition,
Ankrd1−/− mice subjected to pressure overload via TAC,
were also able to maintain a normal cardiac hypertrophic
response, similar to control mice (Bang et al., 2014). These
results were supported by triple (Ankrd1/Ankrd2/Ankrd23)
MARP knockout mice, which also mounted a normal cardiac
hypertrophic response to TAC similar to controls (Bang et al.,
2014).
In vitro and in vivo studies have suggested that ANKRD1
may be coupled to the α-adrenergic associated hypertrophic
pathway (Maeda et al., 2002; Zhong et al., 2015). Ankrd1−/−
mouse hearts and Ankrd1 knockdown by shRNA was shown
to attenuate the hypertrophic response to the α-adrenergic
agonist, phenylephrine (PE) (Zhong et al., 2015). Specifically, PE
infused Ankrd1−/− mice displayed reduced heart size similar to
vehicle controls (Zhong et al., 2015). Co-immunoprecipitation
and immunostaining studies showed that ANKRD1, ERK,
and GATA4 formed a complex at the sarcomeric I band
and nucleus (Zhong et al., 2015). Cardiomyocytes showed
that cardiomyocytes transfected with Ankrd1 siRNA resulted
in diffuse cytoplasmic staining of both ERK1/2 and GATA4,
suggesting that ANKRD1 may serve as a scaffolding protein to
anchor ERK and GATA4 (Zhong et al., 2015). GATA4, which
is a zinc finger transcription factor, plays a pivotal role in
cardiac development and cardiac hypertrophy (Oka et al., 2006).
Recent studies highlight that ERK phosphorylates GATA4 at
S105, leading to enhanced GATA4-DNA binding and activation
of ERK1/2-induced cardiac hypertrophy (van Berlo et al., 2011).
These findings suggested that ANKRD1 acts as a scaffold to
enhance GATA4 phosphorylation via ERK1/2 in the sarcomere
and that the ANKRD1-ERK-GATA4 complex is translocated
to the nucleus upon PE stimulation to regulate hypertrophic
responses (Figure 1). In vitro findings support this mechanism
as cardiomyocytes transfected with Ankrd1 siRNA were shown
to have an attenuated increase in PE-mediated pERK1/2 and
pGATA4 as well as signals related to the nuclear ERK1/2-GATA4
complex (Zhong et al., 2015).
PLASMA MEMBRANE-ASSOCIATED
SCAFFOLDING PROTEINS THAT
REGULATE ERK FUNCTION IN CARDIAC
HYPERTROPHY AND DISEASE
IQ Motif-Containing GTPase Activating
Protein (IQGAP1)
IQGAP1 also acts as a membrane-bound MAPK scaffold to
regulate responses associated with cardiac hypertrophy. IQGAP1
is a highly conserved cytoplasmic scaffold protein that is
ubiquitously expressed (Weissbach et al., 1994). It interacts
with many binding partners and is involved in cytoskeleton,
cell-cell adhesion, protein trafficking, and cell signaling (Smith
et al., 2015). In vivo studies performed in IQGAP1 null
mice, demonstrated a dispensable role for IQGAP1 in heart
function at basal conditions (Sbroggio et al., 2011b). Also,
during chronic pressure overload induced by TAC, IQGAP1
null mice initially displayed a compensatory hypertrophic
response identical to control mice. However, upon prolonged
pressure overload, IQGAP1 null mice displayed unfavorable
cardiac remodeling, contractile dysfunction, impaired cardiac
hypertrophy, and increased apoptosis when compared with
control mice (Sbroggio et al., 2011b). The deletion of IQGAP1
did not affect global MEK-ERK1/2 signaling in the heart, but
selectively impaired the second wave of ERK1/2 activation which
peaked at 4 days in response to pressure overload (Sbroggio et al.,
2011b).
Mechanisms underlying the effects of IQGAP1 in cardiac
hypertrophy may be due to a direct interaction with melusin.
Melusin is a muscle specific protein that binds to the cytoplasmic
domain of β1 integrin, thought to act as a mechanical
stretch sensor (Brancaccio et al., 1999). Melusin expression
increases with various hypertrophic stimuli (cyclic mechanical
stretch, angiotensin-II, endothelin-1, and phenelyphrine)
in neonatal ventricular cardiomyocytes in vitro (Aro et al.,
2013), suggesting a direct role in cardiac hypertrophy. In vivo
studies performed with Melusin-null mice subjected to pressure
overload demonstrated reduced left ventricular hypertrophy,
accelerated development of dilated cardiomyopathy and
contractile dysfunction (Brancaccio et al., 2003). Biphasic effects
of melusin were demonstrated via in vivo studies involving
transgenic mice that selectively overexpressed melusin in the
heart (De Acetis et al., 2005). Cardiac-specific overexpression
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TABLE 1 | Genetic mouse models targeting MAPK scaffold proteins and ERK-mediated signaling in cardiac muscle and their role in cardiac hypertrophy.
MAPK Scaffold
protein
Localization Interactions with MAPK
components
Genetic Mouse
Model
Cardiac phenotype Reference
FHL-1 Sarcomere Scaffolds Raf-1/MEK2/
ERK2 at titin N2B
Fhl1−/− Blunted and beneficial functional
response to pressure overload-induced
hypertrophy in adult heart
Sheikh et al., 2008
ANKRD1 Sarcomere Scaffolds
ERK/GATA4 complex at titin
N2A
Ankrd1−/− Blunted hypertrophic response to chronic
phenylephrine infusion in adult heart
Zhong et al., 2015
IQGAP1 Membrane Scaffolds cRaf-MEK1/2-
ERK1/2 via melusin and FAK
IQGAP1−/− Impaired cardiac hypertrophic response
and increased apoptosis upon prolonged
pressure overload in adult heart
Sbroggio et al.,
2011b
SUR-8 Membrane Scaffolds Ras and Raf Sur-8−/− and
Sur-81/flox ;
Tie2-Cre
Early embryonic lethality
Late embryonic lethality and cardiac
failure
Yi et al., 2010
Erbin disrupts the
Sur-8-Ras-Raf complex
Erbin−/− Exaggerated decompensated cardiac
hypertrophy and heart failure in response
to pressure overload in adult heart
Rachmin et al.,
2014
of melusin induced cardiomyocyte hypertrophy during basal
conditions and retained compensatory hypertrophy during
acute pressure overload; however, the transition toward
heart failure through activation of ERK phosphorylation was
prevented in response to prolonged pressure overload (De
Acetis et al., 2005). Studies performed using transgenic mice
overexpressing melusin also demonstrated cardioprotective
effects of melusin during myocardial infarction as well as
ERK-dependent cardioprotective effects of melusin during
ischemia-reperfusion injury (Penna et al., 2014; Unsold et al.,
2014).
Cross-talk between IQGAP1 and melusin was shown in hearts
of double IQGAP1 null/melusin overexpressing mice, which
demonstrated that the absence of IQGAP1 abrogated melusin-
induced ERK1/2 hyper-phophorylation in both basal conditions
and in response to pressure overload (Sbroggio et al., 2011a).
Co-immunoprecipitation studies in the heart demonstrated
that melusin, IQGAP1 and cRaf-MEK1/2-ERK1/2 formed a
supercomplex with focal adhesion kinase (FAK) at the membrane
(Sbroggio et al., 2011a).
Focal adhesion kinase is a well-known downstream target
of integrin, which is activated by biomechanical stress and
agonists as well as mediates ERK1/2 pathway activation (Lal
et al., 2007). Studies performed in FAK deficient settings showed
that depletion of FAK does not affect the phenotype of non-
stimulated cardiomyocytes, but blocked the up-regulation of
hypertrophic gene markers after pressure overload (Marin et al.,
2008). Furthermore, in vivo studies showed that depletion of
global myocardial FAK by RNA interference or cardiac-specific
FAK knockout mice prevented left ventricular hypertrophy and
the deterioration of cardiac structure after TAC and angiotensin
II infusion (DiMichele et al., 2006; Clemente et al., 2007).
These studies further suggested an important requirement for
FAK in melusin-dependent ERK activation and cardiomyocyte
hypertrophy during pressure overload. Cardiomyocytes treated
with the FAK inhibitor (PF573228) or knockdown (FAK
shRNA) demonstrated an abolishment of melusin-dependent
hypertrophy and reduced ERK1/2 phosphorylation (Sbroggio
et al., 2011a). Thus, FAK, melusin and IQGAP1 were all
shown to be required for ERK1/2 activation in response
to pressure overload (Sbroggio et al., 2011a). These data
altogether suggested a model whereby IQGAP1 scaffolds MAPK
components (c-Raf, MEK1/2 and ERK1/2) at the plasma
membrane via Melusin and FAK to form a supercomplex
to regulate MAPK-ERK signaling and cardiac hypertrophy
(Figure 1).
Suppressor of Ras-8 or Shoc2 (SUR-8)
Suppressor of ras-8, a conserved leucine-rich repeat protein,
was identified as a positive regulator of Ras-mediated signal
transduction in C. elegans (Sieburth et al., 1998). Studies
show that SUR-8 functions as a MAPK scaffold that forms
a ternary complex with Ras and Raf, which then specifically
enhances Ras-induced ERK activation by facilitating the
interaction between Ras and Raf, without any effect on AKT
or JNK activity (Li et al., 2000). Sur-8 conventional knockout
mice were embryonic lethal at early stages (around E8.5) of
mouse development (Yi et al., 2010). Endothelial-specific Sur-8
knockout mice displayed embryonic lethality at later stages of
mouse development as well as multiple cardiac defects (Yi et al.,
2010).
Although the mechanisms underlying how SUR-8 regulates
MAPK signaling in the heart are not well understood, recent
data suggests an intersection with Erbin and cardiac hypertrophy.
Erbin is a LAP [leucine-rich repeat (LRR) and PDZ domain]
family protein (Dillon et al., 2002). Recent studies demonstrated
that LRR- and PDZ-domain-containing proteins play a key
role in assembling protein complexes for signal transduction,
suggesting a signaling role for Erbin (Birrane et al., 2003).
Erbin has been reported to inhibit Ras-mediated activation
of the MAPK pathway via an effect on SUR-8. Specifically,
the LRR domain of Erbin was shown to bind to SUR-
8 and inhibit the interaction of SUR-8 with Ras and Raf
(Dai et al., 2006). Interestingly, Erbin inhibited Raf activation,
but had no effect on Ras activation (Dai et al., 2006).
Furthermore, Erbin overexpression was sufficient to inhibit
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the interaction between SUR-8 and Ras and Raf (Dai et al.,
2006). Suppression of Erbin by shRNA increased the interaction
of SUR-8 with Ras and Raf, resulting in enhanced Raf and ERK
activation (Dai et al., 2006). Co-immunoprecipitation studies
showed that Erbin can form an endogenous complex with SUR-
8 in adult mouse hearts and cardiomyocytes and that this
interaction was lost in Erbin deficient (Erbin−/−) hearts, which
now resulted in p-Raf binding to SUR-8 and thus, ERK1/2
phosphorylation (Rachmin et al., 2014). Interestingly, Erbin
expression is downregulated in adult mouse hearts subjected
to hypertrophic agonists or TAC (Rachmin et al., 2014).
Studies performed in Erbin−/− mice demonstrated that Erbin is
dispensable for the heart during basal conditions; however, when
these mice were subjected to pressure overload they displayed
an exaggerated decompensated cardiac hypertrophy and failure
when compared with controls (Rachmin et al., 2014). In terms
of MAPK-ERK signaling, Erbin−/− mouse hearts exhibited
a twofold increase in p-ERK when compared to controls at
baseline and this effect was even more pronounced (threefold)
under hypertrophic conditions (Rachmin et al., 2014). These
data altogether suggested that Erbin is a negative regulator of
the MAPK scaffold, SUR-8, and can disrupt the Sur-8-Raf-Ras
complex to regulate cardiac hypertrophic signaling (Rachmin
et al., 2014) (Figure 1).
CONCLUSION AND FUTURE
DIRECTIONS
Mitogen activated protein kinase scaffold proteins are emerging
as important players in shaping and localizing the MAPK-ERK
signaling response in cardiac muscle in order to simplify the
response to distinct hypertrophic stimuli (e. g., pressure overload,
Gαq, phenylephrine, etc.). Interestingly, loss of function studies
in mouse models deficient in MAPK scaffold proteins bound to
the sarcomere, such as FHL1 and ANKRD1, suggest a detrimental
role in Gαq and phenylephrine-induced cardiac hypertrophy,
respectively, while studies on MAPK scaffold proteins bound
to the plasma membrane, such as IQGAP1 and Sur-8, suggest
a protective role in mechanical induced-cardiac hypertrophy.
These studies highlight that targeting distinct scaffolds may allow
for more specific MAPK signaling modulation in pathological
states associated with cardiac hypertrophy. Given the complexity
and pleiotropic actions of the MAPK pathway in cardiac
muscle, future studies should also be directed at determining (i)
whether other hypertrophic associated MAPK scaffolds existed
in cardiac muscle, (ii) how MAPK scaffolds insulated themselves
from one another so that cardiac hypertrophic signaling is
stringently regulated and (iii) how MAPK scaffolds regulated
their hypertrophic function in cardiac muscle in a spatiotemporal
manner. Studies focused on developing selective compounds
that target these scaffolds may also provide a means to harness
MAPK signaling to clinically intervene with the deleterious
effects associated with cardiac hypertrophy and failure.
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